View Document Preview and Link Open Document File Size: 17,40 KB Share Result on Facebook
City TARRYTOWN / New York / PARIS / / Company Genzyme / Bayer HealthCare LLC / AMF / Regeneron Pharmaceuticals Inc. / Sanofi / / / Event Business Partnership / Company Listing Change / / IndustryTerm healthcare / therapeutic solutions / consumer healthcare / science-based biopharmaceutical / supply chains / therapeutic applications / diabetes solutions / / MedicalCondition atopic dermatitis / colorectal cancer / rheumatoid arthritis / Atopic Dermatitis Moderate-to / rare inflammatory condition / allergic inflammation / chronic sinusitis / asthma / disease / inflammatory disorders / eczema / chronic inflammatory disease / diabetes / secondary infections / Atopic Dermatitis TARRYTOWN / pronounced pruritus / moderate-to-severe atopic dermatitis / Intense itching / atopic eczema / eye diseases / skin diseases / hypercholesterolemia / / MedicalTreatment investigational therapy / / Organization Dermatology Association / United States Securities and Exchange Commission / National Eczema Association / U.S. Securities and Exchange Commission / American Academy of Dermatology / Medicare / Society for Investigative Dermatology / U.S. Food and Drug Administration / American Academy / FDA / European Academy of Dermatology and Venereology / / Person Julie Block / / / Position Chief Executive Officer / global healthcare leader / Governor / Private / / ProvinceOrState New York / / Technology alpha / therapeutic solutions / SAN / / URL www.regeneron.com / http / SocialTag 
November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I